Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dexamethasone implant versus anti-VEGF versus no adjunct after vitrectomy for proliferative diabetic retinopathy
ChiCTR2100043399Phase 4Recruiting
- Sponsor
- Tianjin Medical University Eye Hospital
- Start
- Feb 2021
- Modality
- Small Molecules, Injectable Hydrogels → Hydrogel Systems → Drug Delivery Systems, Implantable Hydrogels → Hydrogel Systems → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, randomised trial of ozurdex in proliferative diabetic retinopathy (PDR) (3 arms), sponsored by Tianjin Medical University Eye Hospital. Primary endpoints: visual acuity, intraocular pressure and 3 more. Started Feb 2021; status: recruiting.
02
Drugs
ozurdex
03
Conditions
proliferative diabetic retinopathy (PDR)
Beyond the preview
Go deeper on ChiCTR2100043399.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100043399.